Skip to main content

Table 1 Main participants’ criteria

From: Role of residual liver volumetry and function in prediction of liver tolerability after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients: deriving a clinical decision support score

Participants’ criteria Value
Demographic criteria
 • Age (years) Median (min–max) 56.5 (42–75)
 • Sex (Male) Count (%) 166 (65.9%)
Pre-intervention reserve liver functions
 • ALT (IU/L) Median (min–max) 39 (18–74)
 • AST (IU/L) Median (min–max) 43 (20–81)
 • s.albumin (gm/dl) Median (min–max) 3.4 (2.7–3.9)
 • s.bilirubin (mg/dl) Median (min–max) 1.4 (0.9–1.9)
 • Prothrombin concentration (%) Median (min–max) 71 (61–89)
Pre-interventional liver volumetric values and ratios
 • Liver volume (LV) (cm3) Median (min–max) 1714 (1011–3243)
 • Tumor volume (TV) (cm3) Median (min–max) 383 (83–1269)
 • Residual volume (RV) (cm3) Median (min–max) 1336 (827–2418)
 • Residual to liver volumetric ratio (RLVR) Median (min–max) 0.7 (0.43–0.95)
Other evaluated clinical and laboratory parameters
 • Spleen diameter (cm) Median (min–max) 14 (10–20)
 • s.creatinine (mg/dl) Median (min–max) 1.1 (0.8–1.3)
 • Platelets (x103/mm3) Median (min–max) 149 (68–215)
 • Child-Pugh score A5 Count (%) 62 (24.6%)
A6 Count (%) 102 (40.5%)
B7 Count (%) 85 (33.7%)
B8 Count (%) 3 (1.2%)
 • AFP (ng/ml) Median (min–max) 129 (11–1245)
Post intervention measured criteria
 • Time to decompensation (week) Median (min–max) 6 (1–6)
 • Hepatic decompensation Decompensation 82, 32.5%
No decompensation 170, 68.5%
Total 252, 100%